Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
STSI,
Who is this John Joseph McKeon that filed a 13G for ownership of 8.3% of STSI?
Google shows an Orthopedic Surgeon by that name.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8586361
Manny
SIGA news,
ST-246(R) to be Branded Arestvyr(TM) and 12.3 million milestone payment.
SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight pathogens capable of use as bioweapons, today announced that its smallpox antiviral, previously known as ST-246®, would be branded as Arestvyr™ for all purposes, including commercial sales and seeking full marketing approval of the antiviral as a smallpox treatment.
"We are pleased to announce use of the Arestvyr™ name for our proprietary smallpox antiviral treatment," said Dr. Eric A. Rose, Chairman and Chief Executive Officer of SIGA. "ST-246 (Tecovirimat) is becoming increasingly better known around the world as we work to deliver two million courses of our treatment to the United States Government's Strategic National Stockpile. Adopting the Arestvyr™ name is another step in our commercial-stage transformation."
SIGA is also pleased to confirm that it has received payment of the $12.3 million milestone previously invoiced to the U.S. government under SIGA's Strategic National Stockpile contract.
About SIGA Technologies, Inc.
Communities in the United States and around the world face a serious but unmet need for drugs to protect against potentially catastrophic emerging viral pathogens and biological weapons of mass destruction. We are a pharmaceutical company specializing in the development and commercialization of pharmaceutical solutions for some of the most lethal disease-causing pathogens in the world – smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Our business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high-priority threats. Our mission is to disarm dreaded viral diseases and create robust, modern biodefense countermeasures. For more information about SIGA, please visit SIGA's web site at www.siga.com.
The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504
SIGA news,
ST-246(R) to be Branded Arestvyr(TM) and 12.3 million milestone payment.
SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight pathogens capable of use as bioweapons, today announced that its smallpox antiviral, previously known as ST-246®, would be branded as Arestvyr™ for all purposes, including commercial sales and seeking full marketing approval of the antiviral as a smallpox treatment.
"We are pleased to announce use of the Arestvyr™ name for our proprietary smallpox antiviral treatment," said Dr. Eric A. Rose, Chairman and Chief Executive Officer of SIGA. "ST-246 (Tecovirimat) is becoming increasingly better known around the world as we work to deliver two million courses of our treatment to the United States Government's Strategic National Stockpile. Adopting the Arestvyr™ name is another step in our commercial-stage transformation."
SIGA is also pleased to confirm that it has received payment of the $12.3 million milestone previously invoiced to the U.S. government under SIGA's Strategic National Stockpile contract.
About SIGA Technologies, Inc.
Communities in the United States and around the world face a serious but unmet need for drugs to protect against potentially catastrophic emerging viral pathogens and biological weapons of mass destruction. We are a pharmaceutical company specializing in the development and commercialization of pharmaceutical solutions for some of the most lethal disease-causing pathogens in the world – smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Our business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high-priority threats. Our mission is to disarm dreaded viral diseases and create robust, modern biodefense countermeasures. For more information about SIGA, please visit SIGA's web site at www.siga.com.
The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504
VHC,
Major news,as stock is reacting positively.Much more info on IV(read investor don posts).
FirstNet Security
FirstNet is requiring VirnetX security specs in their platform.
About FirstNet ;
http://www.connectednation.org/sites/default/files/bb_pp/cn_policy_brief_-_firstnet_board_meeting_09252012_final.pdf
http://www.commerce.gov/news/press-releases/2012/08/20/acting-us-commerce-secretary-rebecca-blank-announces-board-directors-
From Washington State pg. 2 #38 VirnetX spec TS 33.401
http://www.ntia.doc.gov/files/ntia/wa_siec_response_to_ntia_rfi_06152012.pdf
NOI by Nokia Siemens Network Sept. 25, 2012 VirnetX Security pg.20#5 specs pg.22Footnote 4 TS 33.201
TS 33.401
http://www.ntia.doc.gov/files/ntia/nokia_siemens_networks_comments_11-08-12.pdf
Technical Advisory Board for First Responder Interoperability
(security starts on page 70-81) See VirnetX specs
http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&ved=0CDMQFjAA&url=ftp://ftp.fcc.gov/pub/Daily_Releases/Daily_Business/2012/db0621/FCC-12-68A3.doc&ei=f4i2UMOwEuXZigL54ICICw&usg=AFQjCNGt-8AlQHPTQPwK4-RMRhAQG6fJkA&sig2=Z7_nVHCMyrEKKGRliGPD9Q
More going on in Canada;
Public Safety Broadband Network Pg.20 #5 Footnote 4 Pg.22 TS 33.201 TS 33.401
.Alcatel Lucent Comments
I realize there is a lot of reading here, so I tried to reference certain pages that I felt were important to VirnetX investors. But I found it all interesting.
It is clear that VirnetX security will be foundational for the NGN. Also that all the Tech giants are very aware of this fact. This is getting very exciting.
GLTAL
CORT,
Huge volume spike spike of about 160,000 shares and price rise to 1.60.
Hopefully it's another Director buying.
Stock is now at 1.48,up 6.47% for the day.
Manny
CORT,
Huge volume spike spike of about 160,000 shares and price rise to 1.60.
Hopefully it's another Director buying.
Stock is now at 1.48,up 6.47% for the day.
Manny
BFCF,
Reason for the move higher,is because financing was announced today.
Found info from another poster on IHub:
"wow an otcbb buying a NYSE listed company! lol never seen that before
BFCF buying BXG
http://www.bizjournals.com/southflorida/news/2012/11/28/levans-bbx-capital-will-help-his-bfc.html?ana=yfcpc "
Manny
VHC,
Guilford Securities.Info from a poster on IV.
65 dollar target.
/uploads/84073/files/GIL_112812_132050.pdf
Valuation Analysis
Case study - QCOM's QTL division: we estimate approximately 205 customers licensing technology at royalty rates ranging between 1.5% and 4%
GS 4G/LTE estimated investment cycle (hardware and operating systems): $450b (more than 700 potential players)
Total dollar value of equipment (hardware and operating systems) shipped meeting all requirements set by the 3GPP: ~$125b
Average royalty rate: 100 bps
Potential royalty revenue stream: $1.250 b
Estimated operating margin: 75%
Estimated operating profit: $0.938 b
Estimated LT tax rate: 36%
Estimated LT net income: $0.600 m
LT diluted share count: 0.06 m
Estimated LT EPS: $10.00
Discount at 15% for 8 years: $3.27
Multiple assumption: 20
Price per share: $65
Valuation/price target excludes any potential cash settlements related to on-going litigation
BFCF,
A stock up 14.75% for the day,and more than 50% since original buy deserves attention.
It is unbelievable that there was no interest on IHub.
Volume of 392,800 shares after only 2 hours,has already surpassed the 10 day average of 271,183.
"Avg Vol (10 day)3: 271,183"
http://finance.yahoo.com/q/ks?s=BFCF+Key+Statistics
Manny
BFCF,
Is just incredible.
I sold half at 1.19 to reduce my basis (and fear,lol).
Amazingly,still no interst on IHub.
Manny
STSI,
SAYS ANATABINE SUPPRESSES BRAIN INFLAMMATION IN ANIMALS
2012-11-27 15:25:56.687 GMT
Research Published in European Journal of Pharmacology Shows that Star Scientific's Anatabine Suppresses Brain Inflammation in Animal Model of Alzheimer's Disease and in Blood
PR Newswire
GLEN ALLEN, Va., Nov. 27, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) today announces that new anatabine research has been accepted by and published online in the European Journal of Pharmacology. In a series of studies, researchers at the Roskamp Institute demonstrated that anatabine can suppress brain inflammation in animal models of Alzheimer's disease, inflammation in the blood in mice, and inflammation induced in human blood once removed from the body. This peer-reviewed data supporting the view that anatabine has widespread anti-inflammatory properties was published in a paper, titled, "Anti-inflammatory Activity of Anatabine Via Inhibition of STAT3 Phosphorylation". The anatabine used in these studies is made under Star Scientific's patented process and is the main ingredient in its Anatabloc® dietary supplement.
(logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO)
In one study, the highly inflammatory molecule LPS, which is released from bacteria during human infections, was injected into mice. Subsequently, there were expected large increases in inflammatory molecules in the blood, spleen, and kidney; however, when co-treated with anatabine there were statistically significant large decreases in these inflammatory molecules in the blood, spleen, and kidney. The spleen, in particular, showed marked suppression of inflammatory molecule release during co-treatment with anatabine. In addition, the Roskamp Institute team showed that in a mouse model of Alzheimer's disease, supplementation with anatabine resulted in a significant suppression of inflammatory markers, especially a marker called TNF-Alpha, which is known to be raised in Alzheimer's disease. This finding complements a previous study by the Roskamp Institute showing reduction of the amyloid protein in this mouse model of Alzheimer's after treatment with anatabine. The reduction of the accumulation of amyloid and inflammation in the brain are known to be intimately linked, one increasing the other. Therefore, anatabine's reduction of both amyloid levels and inflammation encourage the hypothesis that anatabine may be a useful treatment for Alzheimer's disease.
Finally, the research team showed that a key mediator of inflammation known as STAT3, which is activated during inflammation, was suppressed in the presence of anatabine in spleen, kidney, and brain of mice, and cultured human neurons and human white cells.
The entire manuscript can be viewed at: http://dx.doi.org/10.1016/j.ejphar.2012.11.017
Dr. Michael Mullan, the CEO and President of the Roskamp Institute stated, "Anatabine continues to demonstrate widespread anti-inflammatory properties in a broad array of pre-clinical models. Given the commonality of inflammatory systems in rodents and humans, there's much reason to expect that anatabine will demonstrate similar properties in humans. In fact, the team went on to demonstrate that in human blood inflamed with LPS, the presence of anatabine dramatically dampened the inflammatory response, a result also included in the paper."
Paul L. Perito, Star Scientific's Chairman, President and COO, stated, "Our research partner, the Roskamp Institute, has once again secured publication of its cutting edge science in the prestigious European Journal of Pharmacology. This publication underscores the worthy productivity of Dr. Michael Mullan
(MD/PhD) and his talented cadre of research scientists, who have better illuminated another contour of anatabine's anti-inflammatory properties. It is one thing to know that our anatabine compound has biological effects; it is far better to have mechanistic data that supports appropriate use and offers a mechanism for those effects."
As previously reported, a human clinical trial analyzing the effects of supplementation with Star Scientific's anatabine compound on individuals with mild to moderate Alzheimer's disease is currently in progress at the Roskamp Institute.
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical and low-TSNA tobacco products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, including with respect to our nutraceutical and low-TSNA tobacco products, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
About Star Scientific
Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism, as well as to reduce the harm associated with the use of tobacco at every level. Over the last several years, through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, and the development of other nutraceuticals and pharmaceuticals. The company also has continued to pursue the development, implementation, and licensing of the technology behind its proprietary StarCured® tobacco curing process, which substantially prevents the formation of carcinogenic toxins present in tobacco and tobacco smoke, primarily the tobacco-specific nitrosamines, or TSNAs and related low-TSNA dissolvable tobacco products. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA; Executive, Scientific & Regulatory Affairs offices in Bethesda, MD, and Washington, DC; and a manufacturing facility in Chase City, VA.
Contact:
Talhia T. Tuck
Vice President, Communications and Investor Relations Star Scientific, Inc.
(202)887-5100
ttuck@starscientific.com
SOURCE Star Scientific, Inc.
Website: http://www.starscientific.com
-0- Nov/27/2012 15:25 GMT
CORT,
Up 5.57% to 1.48 on that huge Insider buy.
Director buys 179,000 shares at average 1.391 for a company he controls.
This is his only holding.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8578773
Manny
CORT,
Up 5.57% to 1.48 on that huge Insider buy.
Director buys 179,000 shares at average 1.391 for a company he controls.
This is his only holding.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8578773
Manny
CORT,
Director buys 179,000 shares at average 1.391 for a company he controls.
This is his only holding.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8578773
Manny
CORT,
Director buys 179,000 shares at average 1.391 for a company he controls.
This is his only holding.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8578773
Manny
STSI,
Looks like someone believes in this company.13D/A form filed by Peter Scott representing a few funds.They own 14% of STSI.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8577845
Manny
STSI,
13D/A form filed by Peter Scott representing a few funds.They own 14% of STSI.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8577845
Manny
STSI,
13D/A form filed by Peter Scott representing a few funds.They own 14% of STSI.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8577845
Manny
ACFN,
Was a great buy under 7.5.It is now 8.06,with great potential.
News,
GridSense, an Acorn Energy Company, Announces an Expanded Order for Pole-top & Underground TransformerIQ™ Monitors from a M... Date : 11/26/2012 @ 1:21PM
GridSense, an Acorn Energy Company, Announces an Expanded Order for Pole-top & Underground TransformerIQ™ Monitors from a M...
SACRAMENTO, Calif., Nov. 26, 2012 /PRNewswire/ -- GridSense, an Acorn Energy (NASDAQ: ACFN) company that develops and markets advanced monitoring solutions for the electric power industry, announced the sale of an additional 200 TransformerIQ™ advanced monitoring units to a major California utility. The 200 TransformerIQ™ devices will be used to monitor and secure valuable data from overhead and underground transformers dispersed throughout the utility's residential distribution grid. The total order for 700 units is valued at over $1 million.
(Logo: http://photos.prnewswire.com/prnh/20120504/NY01341LOGO )
(Logo: http://photos.prnewswire.com/prnh/20120426/NY96114LOGO )
"This sale is the second step in the ongoing relationship we are developing with this major California utility," said Lindon Shiao, Chief Executive of GridSense. "I expect that once these orders are fulfilled, the technology deployed and the benefits proven we will have further positive interaction with this utility on their fleet of over 100,000 transformers."
About GridSense Inc.
GridSense is a smart grid technology company dedicated to providing innovative, practical and cost effective monitoring solutions to the electric power industry. Utilizing in-depth industry knowledge and understanding of utility requirements, we provide technology and services that help the industry address the limitations of old and aging infrastructure. We apply experience and technical know-how with new insight and ideas to create intelligent, reliable and leading edge technologies that add value to our customers and shape the future of the modern electrical power system.
About Acorn Energy, Inc.
Acorn Energy, Inc., the digital energy company, is a holding company focused on making energy better by providing digital solutions for energy infrastructure asset management. The four businesses in which we have controlling interests improve the world's energy infrastructure by making it: more secure - providing security solutions for underwater energy infrastructure (DSIT); more reliable - providing condition-based monitoring to critical assets on the electric grid (GridSense, OmniMetrix) and more productive and efficient - increasing oil and gas production while lowering costs through use of permanent ultra-high sensitive seismic tools that allow for a more precise picture of reservoirs (US Seismic). For more information visit: http://www.acornenergy.com.
ACFN,
Was a great buy under 7.5.It is now 8.06,with great potential
News,
GridSense, an Acorn Energy Company, Announces an Expanded Order for Pole-top & Underground TransformerIQ™ Monitors from a M... Date : 11/26/2012 @ 1:21PM
GridSense, an Acorn Energy Company, Announces an Expanded Order for Pole-top & Underground TransformerIQ™ Monitors from a M...
SACRAMENTO, Calif., Nov. 26, 2012 /PRNewswire/ -- GridSense, an Acorn Energy (NASDAQ: ACFN) company that develops and markets advanced monitoring solutions for the electric power industry, announced the sale of an additional 200 TransformerIQ™ advanced monitoring units to a major California utility. The 200 TransformerIQ™ devices will be used to monitor and secure valuable data from overhead and underground transformers dispersed throughout the utility's residential distribution grid. The total order for 700 units is valued at over $1 million.
(Logo: http://photos.prnewswire.com/prnh/20120504/NY01341LOGO )
(Logo: http://photos.prnewswire.com/prnh/20120426/NY96114LOGO )
"This sale is the second step in the ongoing relationship we are developing with this major California utility," said Lindon Shiao, Chief Executive of GridSense. "I expect that once these orders are fulfilled, the technology deployed and the benefits proven we will have further positive interaction with this utility on their fleet of over 100,000 transformers."
About GridSense Inc.
GridSense is a smart grid technology company dedicated to providing innovative, practical and cost effective monitoring solutions to the electric power industry. Utilizing in-depth industry knowledge and understanding of utility requirements, we provide technology and services that help the industry address the limitations of old and aging infrastructure. We apply experience and technical know-how with new insight and ideas to create intelligent, reliable and leading edge technologies that add value to our customers and shape the future of the modern electrical power system.
About Acorn Energy, Inc.
Acorn Energy, Inc., the digital energy company, is a holding company focused on making energy better by providing digital solutions for energy infrastructure asset management. The four businesses in which we have controlling interests improve the world's energy infrastructure by making it: more secure - providing security solutions for underwater energy infrastructure (DSIT); more reliable - providing condition-based monitoring to critical assets on the electric grid (GridSense, OmniMetrix) and more productive and efficient - increasing oil and gas production while lowering costs through use of permanent ultra-high sensitive seismic tools that allow for a more precise picture of reservoirs (US Seismic). For more information visit: http://www.acornenergy.com.
How quickly did you find out that you can't take Anatabloc because of Acid Reflux?
My mother,who is 77 years old had a problem with Acid reflux before starting Anatabloc
She has had this problem for many years.She recently started to really feel bad from acid reflux,and we went to the doctor.
Unfortunately,she developed A-Fib,and is now on medication to try and control it.Two of my mother's sisters have had strokes,so there is some heart problems in her family.
I stopped the Anatabloc just in case it caused some of the problems.
I have not seen any disclaimer or information the A-Bloc can cause Acid Reflux.
Thanks,
Manny
CORT,
Bought some at 1.40 as a possible January Effect play on tax loss selling in November and December.
Stock has been holding around this price.
http://finviz.com/quote.ashx?t=cort&ty=c&ta=1&p=d
Manny
CORT,
Bought some at 1.40 as a possible January Effect play on tax loss selling in November and December.
Stock has been holding around this price.
http://finviz.com/quote.ashx?t=cort&ty=c&ta=1&p=d
Manny
Found this,
Gapping Down
KITD -50% (announced restatement of prior period financial statements and postponement of third quarter 2012 results; this morning co's former Chairman/CEO urged company to discuss acquisition offer and conduct open and transparent sale process
Of course there could be some positive news coming from the studies.
There is confirmation from the study posted today that inflammation can cause cancer.
I guess that was the pop in the stock.
Let's see what the studies tell us.
Manny
STSI,
From a poster on IV:
Newcomer to Anatabloc and Star Scientific
I've been investigating the company and Anatabloc for a couple days. I've investigated in the past inflammation so am somewhat familiar with inflammatory diseases and the disease process.
What I'm noticing is that there are some people that have great results and some that don't have any results. Those who are familiar with other anti-inflammatory drugs, that is very common. The only ones that seem to be fairly consistent are those that work very directly at inhibiting the inflammation process such as steroids like prednisone.
Looking at the anatabine research, the company indicates that anatabine "appears" to deactivate a protein within the cell. But interestingly, the "Flint/CRP study" showed that overall, 42% patients had a decrease in CRP after only one month with anatabine supplements. On the other hand, 61% of diabetic subjects taking metformin had a CRP reduction. Given not all patients benefited from a one month period of taking anatabine. But also given that some people report that anatabine works wonders for them, one hypothesis is that the CRP is caused by multiple things and anatabine only helps a subset of people which may have CRP caused by something anatabine can help with.
It is interesting speculation. Hopefully, more research will show what is happening.
IMSC,
Another Form 4,this time by CEO,exercising 100,000 shares at .20,
and another 43,600 shares which he gifted.
He held no shares until this exercise,and he had until November 20,2018 to exercise.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8574980
I hope these Insiders are getting prepared for some windfall profits in the near future.
Manny
IMSC,
Another Form 4,this time by CEO,exercising 100,000 shares at .20,
and another 43,600 shares which he gifted.
He held no shares until this exercise,and he has until November 20,2018 to exercise.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8574980
I hope these Insiders are getting prepared for some windfall profits in the near future.
Manny
IMSC,
Form-4 just filed by Chief Financial Officer.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8574804
He just exercised 25,000 shares at .20,and 75,000 shares at .17.
He had till 12/30/2013 to exercise the first bunch,and 2/5/2014 to exercise the second.
Is he expecting something?
Manny
IMSC,
Form-4 just filed by Chief Financial Officer.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8574804
He just exercised 25,000 shares at .20,and 75,000 shares at .17.
He had till 12/30/2013 to exercise the first bunch,and 2/5/2014 to exercise the second.
Is he expecting something?
Manny
CLSN,
It's articles like this that are stoking the fire.
http://www.reuters.com/article/2012/06/19/us-celsion-thermodox-idUSBRE85I1IL20120619
Quote:"Certainly this is a $1 billion drug," Tardugno told Reuters in an interview. He was not ready to predict multiple billions just yet and noted that all, of course, depends on positive data from its pivotal late stage trial.
Manny
.92 trades in after hours on next Tuesday's conference call announcement.
Manny
VHC,
Bought some at .62-.625.
Looks like this Director who bought 50,000 shares from .55 to .635 thinks this company is worth current pricing.
AUGT-Director buys 50,000 shares at prices from .55 to .635.he had only 4,000 shares before this..
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8572672
Manny
I am definitely not selling here.
I remember a stock called AVII,which has since changed their name to SRPT.
I refused to buy in the 3 dollar area after the company did a 6 for 1 reverse split .
It is now at 26.9,and was at a high of 45,after the company announced good news on their Muscular Dystrophy drug.
HDY has a deal with Tullow that could if successful bring it to major new highs even with a split.
IMHO,
Manny
ACFN,
I posted that ACFN would possibly be a good buy from the recent lows if the market recovers.This was based on Insider buying and deals made by the company's divisions.
Today,more good news:
GridSense™, an Acorn Energy Company, is named a 2012 GoingGreen "Global 200 Top Company to Watch"
Print
Alert
Acorn Energy, Inc. (MM) (NASDAQ:ACFN)
Intraday Stock Chart
Today : Tuesday 20 November 2012
Click Here for more Acorn Energy, Inc. (MM) Charts.
SACRAMENTO, Calif., Nov. 20, 2012 /PRNewswire/ -- GridSense™, an Acorn Energy (NASDAQ: ACFN) company that develops and markets advanced monitoring solutions for the electric power industry, has been named by AlwaysOn one of its GoingGreen 200 Top Global Companies to Watch for 2012. AlwaysOn is the premier source for the analysis and prediction of top trends and top companies in Greentech and other industries. Among the companies AlwaysOn highlighted prior to their breakouts include Google, Salesforce.com, Skype and Tesla. The GoingGreen Global 200 celebrates companies that "disrupt the established energy, manufacturing and technology worlds" and pioneer "new ways to deliver efficient products to a resource-hungry world."
(Logo: http://photos.prnewswire.com/prnh/20120426/NY96114LOGO )
(Logo: http://photos.prnewswire.com/prnh/20120504/NY01341LOGO )
By winning this award GridSense now becomes the second Acorn Energy Company to be honored with a GoingGreen Award by AlwaysOn. In 2009 CoaLogix was a GoingGreen award winner, and in 2010 CoaLogix was chosen by AlwaysOn as one of the GoingGreen East Winners. Acorn successfully completed the sale of CoaLogix in 2011 for $101 million to Energy Capital Partners.
"We are honored to be recognized by GoingGreen," says GridSense™ CEO Lindon Shiao. "Our intelligent monitoring solutions for transformers and overhead lines are engineered to help utilities provide more reliable and efficient service, helping them maximize current resources and minimize the need for new generation facilities. It's great to be recognized for making progress in those areas."
The GridSense™ focus on optimization stems from the utility industry's dual challenges of increased efficiency mandates combined with minimal additional resource allocation. Utilities must do more with what they have, including; adapt to the disruptive influence of renewables, minimize downtime, and meet increasingly stringent efficiency mandates. GridSense™ monitoring solutions are designed to help utilities achieve these goals.
The GoingGreen Global 200 Top Companies to Watch were selected by a panel of industry experts that included the AlwaysOn editorial team, as well as its venture capital and enterprise partners.
About GridSense Inc.
GridSense is a smart grid technology company dedicated to providing innovative, practical and cost effective monitoring solutions to the electric power industry. Utilizing in-depth industry knowledge and understanding of utility requirements, we provide technology and services that help the industry address the limitations of old and aging infrastructure. We apply experience and technical know-how with new insight and ideas to create intelligent, reliable and leading edge technologies that add value to our customers and shape the future of the modern electrical power system. For more information visit (www.gridsense.com).
About Acorn Energy, Inc.
Acorn Energy, Inc., the digital energy company is a holding company focused on making energy better by providing digital solutions for energy infrastructure asset management. The four businesses in which it has controlling interests, improve the world's energy infrastructure by making it: more secure - providing security solutions for underwater energy infrastructure (DSIT); more reliable - providing condition-based monitoring to critical assets on the electric grid (GridSense, OmniMetrix) and more productive and efficient - increasing oil and gas production while lowering costs through use of permanent ultra-high sensitive seismic tools that allow for a more precise picture of reservoirs (US Seismic). For more information visit: http://www.acornenergy.com
This stock is about a 1% position,but will increase if stock stays lower.
No big deal.I have bigger bets elsewhere that have been pretty successful,if you check my posts.
I posted how I felt,and now back to the bigger fish to fry.
Manny
Jus don't post your great trade at 1.15 when stock is trading at .87.
It just like spitting in the long's face.
IMHO of course.
Manny
Great timely post when stock is .87.
Why bother.
Manny
NAVB,
Platinum Montaur has promised to fund their needs if any extra money was needed.
That is why Montaur sold NAVB shares recently to have funds to fund the company.
Here is an old post from DDbuyer of IV:
NAVB,
from DDBuyer on IV:
CRL affect on NAVB cash position
At the end of Q2 Navidea reported $17 million in cash. Burn rate was running a little under $5 million a quarter, so cash on hand right now is probably ~$14 million. The $15 million credit line is untouched, and Mike Goldberg at Montaur confirmed on yesterdays conference call that Montaur remains committed to Navidea.
That gives them ~$29 million in available cash. At the current burn rate that will last almost 18 months.
This manufacturing issue will be resolved LONG before then, even under the worst case scenario.
Cash is not an issue...
DDbuyer
NAVB,
Now at 2.29.
Could be a great buy as a tax loss selling candidate with PDUFA coming in April.I have it at much higher prices.
It is a heavily Shorted stock,but institutions now own 23% of shares.
Also,this was posted on the NAVB old timers board:
There are now 10 institutions with 500k or more shares...
...and EVERY one of them increased their positions during the last quarter (4 of them by 600,000 shares or more). I'm really impressed by the addition of Nomura Holdings which bought 2 million shares to establish their position.
This is as of of 9/30...which was AFTER the news of the FDA delay and BEFORE the expeditious and successful resubmission of the NDA.
Obviously there are a number of professionals who believe in our company's prospects.
http://www.nasdaq.com/symbol/navb/institutional-holdings